Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing preclinical and discovery programs, including selective BRM targeting non-small-cell lung cancer; and selective ARID1B modulators for bladder, ovarian, and endometrial cancer. It has a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.